All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-08-21T11:14:30.000Z

Management of drug-related adverse events in patients with steroid-refractory cGvHD

Aug 21, 2024
Share:
Learning objective: After reading this article, learners will be able to describe the latest data relating to treatment of SR-GvHD.

During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the management of drug-related adverse events in patients with steroid-refractory chronic graft-versus-host disease (cGvHD). The recorded discussion was chaired by Zinaida Peric, and featured Yi-Bin Chen, Amin Alousi, Florent Malard, Mohamad Mohty, Arnon Nagler, Steven Pavletic, and Robert Zeiser.

Management of drug related adverse events in patients with steroid refractory GvHD

The steering committee discussed how to define steroid intolerance and how this definition can change for each patient based on side effects and treatment scheduling. In addition, the steering committee spoke about how to approach steroid tapering and appropriate dosing of steroids, and how to evaluate the response of steroids and to ruxolitinib. They also discussed the choice of drug for cGvHD, taking patient factors and side effects into account.

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
3 votes - 63 days left ...

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox